Candriam S.C.A. Has $6.16 Million Holdings in Exelixis, Inc. $EXEL

Candriam S.C.A. decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 50.0% during the 1st quarter, Holdings Channel reports. The firm owned 143,557 shares of the biotechnology company’s stock after selling 143,661 shares during the quarter. Candriam S.C.A.’s holdings in Exelixis were worth $6,157,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Hsbc Holdings PLC raised its stake in Exelixis by 152.9% during the 1st quarter. Hsbc Holdings PLC now owns 65,978 shares of the biotechnology company’s stock worth $2,837,000 after buying an additional 39,894 shares during the period. Roman Butler Fullerton & Co. bought a new position in shares of Exelixis in the first quarter valued at approximately $675,000. Sumitomo Mitsui Trust Group Inc. grew its stake in Exelixis by 0.5% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock valued at $2,549,000 after purchasing an additional 281 shares during the period. Childress Capital Advisors LLC purchased a new stake in Exelixis during the first quarter worth about $206,000. Finally, Flatrock Wealth Partners LLC bought a new position in shares of Exelixis during the 1st quarter valued at approximately $270,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Down 0.8%

EXEL stock opened at $56.04 on Tuesday. The business has a 50 day moving average of $51.93 and a 200 day moving average of $46.53. The firm has a market cap of $14.09 billion, a PE ratio of 18.62, a price-to-earnings-growth ratio of 1.63 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $57.57.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. During the same period last year, the firm posted $0.55 earnings per share. Exelixis’s revenue was up 10.0% compared to the same quarter last year. On average, research analysts expect that Exelixis, Inc. will post 3.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Christopher J. Senner sold 34,901 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the sale, the chief financial officer owned 952,317 shares in the company, valued at approximately $47,615,850. The trade was a 3.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 32,110 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the sale, the executive vice president owned 357,638 shares in the company, valued at approximately $17,813,948.78. This trade represents a 8.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 219,170 shares of company stock valued at $10,620,641. Insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on EXEL. Royal Bank Of Canada raised their price objective on shares of Exelixis from $43.00 to $46.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Wells Fargo & Company lifted their price target on Exelixis from $40.00 to $49.00 and gave the company an “equal weight” rating in a research report on Monday. Stifel Nicolaus increased their target price on Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Citizens Jmp increased their price target on shares of Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a research report on Wednesday, June 24th. Finally, Barclays raised their price objective on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a research note on Monday, April 20th. Nine research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Exelixis currently has an average rating of “Hold” and a consensus price target of $48.53.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.